KR20110067103A - 파라세타몰을 포함하는 액체 약학적 제제 - Google Patents

파라세타몰을 포함하는 액체 약학적 제제 Download PDF

Info

Publication number
KR20110067103A
KR20110067103A KR1020117006413A KR20117006413A KR20110067103A KR 20110067103 A KR20110067103 A KR 20110067103A KR 1020117006413 A KR1020117006413 A KR 1020117006413A KR 20117006413 A KR20117006413 A KR 20117006413A KR 20110067103 A KR20110067103 A KR 20110067103A
Authority
KR
South Korea
Prior art keywords
total volume
pharmaceutical formulation
amount
relative
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117006413A
Other languages
English (en)
Korean (ko)
Inventor
프란체스카 마리오티
파올로 스카르페티
로렐라 라니
마우로 발렌티
Original Assignee
아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 filed Critical 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이
Publication of KR20110067103A publication Critical patent/KR20110067103A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020117006413A 2008-10-09 2009-09-28 파라세타몰을 포함하는 액체 약학적 제제 Ceased KR20110067103A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08425654.4 2008-10-09
EP08425654 2008-10-09

Publications (1)

Publication Number Publication Date
KR20110067103A true KR20110067103A (ko) 2011-06-21

Family

ID=40282272

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117006413A Ceased KR20110067103A (ko) 2008-10-09 2009-09-28 파라세타몰을 포함하는 액체 약학적 제제

Country Status (14)

Country Link
US (1) US20120115958A1 (enExample)
EP (1) EP2349207B1 (enExample)
JP (1) JP2012505172A (enExample)
KR (1) KR20110067103A (enExample)
CN (1) CN102159184B (enExample)
AR (1) AR073793A1 (enExample)
AU (1) AU2009301296A1 (enExample)
BR (1) BRPI0919796A2 (enExample)
CA (1) CA2737391A1 (enExample)
EA (1) EA018401B1 (enExample)
GE (1) GEP20135723B (enExample)
MX (1) MX2011003695A (enExample)
UA (1) UA103906C2 (enExample)
WO (1) WO2010040652A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2595603A1 (en) * 2010-07-21 2013-05-29 Alcon Research, Ltd. Pharmaceutical composition with enhanced solubility characteristics
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
EP3233055B1 (en) * 2014-12-20 2024-12-25 Troikaa Pharmaceuticals Ltd Injectable formulations of paracetamol
DK3800177T3 (da) 2015-12-22 2025-03-31 Zogenix International Ltd Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
US10689324B2 (en) 2015-12-22 2020-06-23 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
RU2021106383A (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
TWI620577B (zh) * 2016-11-23 2018-04-11 乙醯胺酚及曲馬多共溶複方止痛口服液
US10682317B2 (en) * 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
GR1009462B (el) * 2017-10-05 2019-02-15 Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. Ποσιμο φαρμακευτικο διαλυμα με συγκαλυμμενη γευση
US20210290532A1 (en) * 2017-11-02 2021-09-23 Max Spielberg Pharmaceutical syrup formulation or suspension
CN110115708A (zh) * 2018-02-07 2019-08-13 保瑞药业股份有限公司 乙酰胺酚及曲马多共溶复方止痛口服液
GR1009630B (el) * 2018-03-14 2019-10-25 Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. Ποσιμα διαλυματα που περιλαμβανουν τραμαδολη και ακεταμινοφαινη
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US10517841B1 (en) 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
WO2020105005A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
NL2024161B1 (en) * 2019-11-05 2021-07-20 Mperium B V Pharmaceutical liquid composition, kit of parts comprising the pharmaceutical liquid composition, and method for preparing the pharmaceutical liquid composition
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
JP2025516857A (ja) * 2022-05-25 2025-05-30 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Ｓｇｌｔ－２阻害薬を含む水性医薬組成物
PL4368171T3 (pl) 2022-11-08 2025-09-22 Laboratorios Ern S.A. Roztwór doustny paracetamolu

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
US8128958B2 (en) * 2003-11-10 2012-03-06 Astellas Pharma Inc. Sustained release pharmaceutical composition
US20080139528A1 (en) * 2003-12-10 2008-06-12 Pujara Chetan P Cefdinir oral suspension
US20060093629A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
WO2007070504A2 (en) * 2005-12-13 2007-06-21 Morton Grove Pharmaceuticals, Inc. Stable and palatable oral liquid sumatriptan compositions
US20080085892A1 (en) * 2006-08-31 2008-04-10 Sangeetha Kandeepan Liquid dosage form of acetaminophen

Also Published As

Publication number Publication date
AR073793A1 (es) 2010-12-01
UA103906C2 (ru) 2013-12-10
MX2011003695A (es) 2011-08-17
GEP20135723B (en) 2013-01-10
EA201170543A1 (ru) 2011-10-31
CN102159184A (zh) 2011-08-17
JP2012505172A (ja) 2012-03-01
US20120115958A1 (en) 2012-05-10
EP2349207B1 (en) 2015-05-13
BRPI0919796A2 (pt) 2015-12-15
AU2009301296A1 (en) 2010-04-15
CN102159184B (zh) 2013-09-04
WO2010040652A1 (en) 2010-04-15
EA018401B1 (ru) 2013-07-30
CA2737391A1 (en) 2010-04-15
EP2349207A1 (en) 2011-08-03

Similar Documents

Publication Publication Date Title
CN102159184B (zh) 含有对乙酰氨基酚的液体药物制剂
US11406712B2 (en) Phenylephrine-containing liquid formulations
US7101572B2 (en) Taste masked aqueous liquid pharmaceutical composition
US10238640B2 (en) Pharmaceutical suspension composition
KR101458772B1 (ko) 페닐에프린을 함유하는 약제학적 현탁액 및 이의 제조 방법
EP1438026B1 (en) Taste masking spill-resistant formulation
US12629422B2 (en) Agave syrup formulation or suspension for active pharmaceutical agents
KR101317657B1 (ko) 염료 비함유 약제학적 현탁액 및 관련된 방법
EP1809250B1 (en) Dye-free pharmaceutical suspensions comprising sorbitol as a non-reducing sweetener and at least one active agent
JP5611672B2 (ja) 経口ゼリー剤
WO2019174755A1 (en) Oral solutions comprising tramadol and acetaminophen
JPH085784B2 (ja) シロツプ剤
EP4279062A1 (en) Liquid composition and its use, treatment method and kit
EP4108233A1 (en) Oral solution comprising a cinacalcet salt
HK1123993B (en) Phenylephrine-containing liquid formulations
HK1123993A (en) Phenylephrine-containing liquid formulations

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110321

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140728

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151208

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160215

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20151208

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I